Novo Nordisk A/S (NYSE:NVO) Stock Acquired Rep. C. Scott Franklin

Key Points

• Representative C. Scott Franklin purchased shares of Novo Nordisk A/S (NYSE:NVO) between $15,001 and $50,000 on August 4th, according to a filing disclosed on August 14th.
• Despite a 2.9% increase in stock price, Novo Nordisk A/S reported earnings of $0.97 per share, surpassing analyst expectations of $0.93.
• The company's recent dividend payout was announced at $0.4119, representing a significant dividend yield of 240.0%.

Representative C. Scott Franklin (R-Florida) recently bought shares of Novo Nordisk A/S NYSE: NVO. In a filing disclosed on August 14th, the Representative disclosed that they had bought between $15,001 and $50,000 in Novo Nordisk A/S stock on August 4th. The trade occurred in the Representative's "FIDELITY TRADITIONAL IRA" account.

Representative C. Scott Franklin also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Comcast NASDAQ: CMCSA on 8/4/2025.
• Purchased $1,001 - $15,000 in shares of Novo Nordisk A/S NYSE: NVO on 8/4/2025.
• Sold $15,001 - $50,000 in shares of Comcast NASDAQ: CMCSA on 8/4/2025.
• Sold $1,001 - $15,000 in shares of United Parcel Service NYSE: UPS on 7/22/2025.
• Sold $50,001 - $100,000 in shares of United Parcel Service NYSE: UPS on 7/22/2025.
• Sold $15,001 - $50,000 in shares of Visa NYSE: V on 6/16/2025.
• Sold $15,001 - $50,000 in shares of Apple NASDAQ: AAPL on 6/16/2025.
• Sold $1,001 - $15,000 in shares of Alphabet NASDAQ: GOOG on 6/16/2025.
• Sold $1,001 - $15,000 in shares of Merck & Co., Inc. NYSE: MRK on 6/16/2025.
• Sold $15,001 - $50,000 in shares of McDonald's NYSE: MCD on 6/16/2025.

Novo Nordisk A/S Price Performance

NYSE NVO traded up $0.43 during trading hours on Tuesday, reaching $54.18. 19,060,462 shares of the stock traded hands, compared to its average volume of 11,646,474. The stock has a 50 day simple moving average of $64.52 and a two-hundred day simple moving average of $70.02. Novo Nordisk A/S has a 1 year low of $45.05 and a 1 year high of $139.74. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56. The company has a market cap of $241.91 billion, a price-to-earnings ratio of 14.88, a price-to-earnings-growth ratio of 1.80 and a beta of 0.63.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.93 by $0.04. The firm had revenue of $11.69 billion for the quarter, compared to the consensus estimate of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. On average, analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The company also recently declared a semi-annual dividend, which will be paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th will be given a dividend of $0.4119 per share. The ex-dividend date is Monday, August 18th. This represents a yield of 240.0%. Novo Nordisk A/S's dividend payout ratio (DPR) is presently 45.05%.

Analyst Ratings Changes

Several research analysts have recently commented on NVO shares. BNP Paribas Exane upgraded Novo Nordisk A/S from an "underperform" rating to a "neutral" rating and set a $54.00 price objective on the stock in a report on Wednesday, August 13th. BNP Paribas upgraded Novo Nordisk A/S from an "underperform" rating to a "neutral" rating in a report on Wednesday, August 13th. Dbs Bank downgraded Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. HSBC downgraded Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $57.00 price objective on the stock. in a report on Thursday, July 31st. Finally, Wall Street Zen downgraded Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Saturday, August 2nd. Three analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $81.00.

Institutional Trading of Novo Nordisk A/S

Large investors have recently bought and sold shares of the company. Strategic Investment Solutions Inc. IL boosted its position in shares of Novo Nordisk A/S by 2,727.3% in the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after purchasing an additional 300 shares in the last quarter. Copeland Capital Management LLC lifted its position in Novo Nordisk A/S by 184.8% in the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock valued at $27,000 after acquiring an additional 255 shares in the last quarter. North Capital Inc. bought a new position in Novo Nordisk A/S in the 1st quarter valued at approximately $27,000. Park Square Financial Group LLC bought a new position in Novo Nordisk A/S in the 4th quarter valued at approximately $29,000. Finally, Stone House Investment Management LLC bought a new position in Novo Nordisk A/S in the 1st quarter valued at approximately $30,000. 11.54% of the stock is owned by institutional investors.

About Representative Franklin

Scott Franklin (Republican Party) is a member of the U.S. House, representing Florida's 18th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027. Franklin (Republican Party) is running for re-election to the U.S. House to represent Florida's 18th Congressional District. He declared candidacy for the 2026 election. Scott Franklin was born in Thomaston, Georgia. Franklin graduated from Lakeland High School. He served in the U.S. Navy from 1986 to 2000 and the U.S. Navy Reserve from 2000 to 2012. Franklin earned a B.S. from the United States Naval Academy in 1986 and an M.B.A. from Embry-Riddle Aeronautical University in 1994. Franklin's career experience includes owning an insurance agency and working as a naval aviator with the U.S. Navy.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.